Globus previously considered NuBone to fall under the minimally manipulated tissue exemption from premarket notification, but the FDA determined it required 510(k) clearance in March 2008. The company maintained communication with the FDA but discontinued NuBone in 2010.
The complaint of an alleged violation does not include patient safety issues, and the amended complaint does not allege intentional wrongdoing by the company or Mr. Paul.
More Articles on Orthopedic Devices:
Orthofix Names Brad Niemann Senior Vice President of Commercial Operations for Global Business
Orchid Acquires Sandvik Medical Solutions
Symmetry Medical 4Q Revenue Drops 12%
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
